☰

Ahmet Cingoz - Publications

Affiliations: 
Koc University, Turkey 
Area:
Cancer
Tree Info Similar researchers PubMed Report error

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Cingöz A, Ozyerli-Goknar E, Morova T, Seker-Polat F, Selvan ME, Gümüş ZH, Bhere D, Shah K, Solaroglu I, Bagci-Onder T. Editorial Expression of Concern: Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. Oncogene. PMID 39044011 DOI: 10.1038/s41388-024-03110-4  0.306
2021 Cingöz A, Ozyerli-Goknar E, Morova T, Seker-Polat F, Esai Selvan M, Gümüş ZH, Bhere D, Shah K, Solaroglu I, Bagci-Onder T. Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. Oncogene. 40: 3201-3216. PMID 33767436 DOI: 10.1038/s41388-021-01697-6  0.485
2020 Senbabaoglu F, Aksu AC, Cingoz A, Seker-Polat F, Borklu-Yucel E, Solaroglu İ, Bagci-Onder T. Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma. Frontiers in Neuroscience. 14: 578316. PMID 33390879 DOI: 10.3389/fnins.2020.578316  0.319
2020 Sur-Erdem I, Muslu K, Pınarbası N, Altunbek M, Seker-Polat F, Cingöz A, Aydın SO, Kahraman M, Culha M, Solaroglu I, Bagcı-Önder T. TRAIL-conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway. Neurological Research. 1-9. PMID 32715947 DOI: 10.1080/01616412.2020.1796378  0.545
2019 Saraç H, Morova T, Pires E, McCullagh J, Kaplan A, Cingöz A, Bagci-Onder T, Önder T, Kawamura A, Lack NA. Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer. Oncogene. PMID 31822799 DOI: 10.1038/S41388-019-1116-8  0.349
2019 Ozyerli-Goknar E, Sur-Erdem I, Seker F, Cingöz A, Kayabolen A, Kahya-Yesil Z, Uyulur F, Gezen M, Tolay N, Erman B, Gönen M, Dunford J, Oppermann U, Bagci-Onder T. The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma Cell Death and Disease. 10: 894. PMID 31772153 DOI: 10.1038/S41419-019-2107-Y  0.563
2019 Seker F, Cingoz A, Sur-Erdem İ, Erguder N, Erkent A, Uyulur F, Esai Selvan M, Gümüş ZH, Gönen M, Bayraktar H, Wakimoto H, Bagci-Onder T. Identification of as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling. Cancers. 11. PMID 31731490 DOI: 10.3390/Cancers11111651  0.399
2019 Kaya-Aksoy E, Cingoz A, Senbabaoglu F, Seker F, Sur-Erdem I, Kayabolen A, Lokumcu T, Sahin GN, Karahuseyinoglu S, Bagci-Onder T. The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme. Cell Death Discovery. 5: 64. PMID 30774992 DOI: 10.1038/S41420-019-0144-Z  0.518
2017 Kurt IC, Sur I, Kaya E, Cingoz A, Kazancioglu S, Kahya Z, Toparlak OD, Senbabaoglu F, Kaya Z, Ozyerli E, Karahüseyinoglu S, Lack NA, Gümüs ZH, Onder TT, Bagci-Onder T. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL. Cell Death & Disease. 8: e2897. PMID 28661478 DOI: 10.1038/Cddis.2017.288  0.544
2017 Idot, Sur l, Muslu K, Cingöz A, Önder TB. Abstract 4164: TRAIL resistance of glioblastoma cells is associated with DNA damage signalling network Cancer Research. 77: 4164-4164. DOI: 10.1158/1538-7445.Am2017-4164  0.344
2016 Erkoc P, Cingöz A, Onder TB, Kizilel S. Quinacrine Mediated Sensitization of Glioblastoma (GBM) Cells to TRAIL through MMP-Sensitive PEG Hydrogel Carriers. Macromolecular Bioscience. PMID 27762493 DOI: 10.1002/Mabi.201600267  0.494
2016 Senbabaoglu F, Cingoz A, Kaya E, Kazancioglu S, Lack NA, Acilan C, Bagci-Onder T. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme. Cancer Biology & Therapy. 17: 546-57. PMID 27029345 DOI: 10.1080/15384047.2016.1167292  0.561
2016 Cingoz A, Gumus ZH, Gonen M, Bagci-Onder T. Dres-12. Profiling Of Different Gbm Cell Populations With Varying Apoptotic Thresholds Identifies Igfbp-2 As A Novel Mediator Of Trail Resistance Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.222  0.441
2016 Senbabaoglu F, Cingoz A, Kaya E, Kazancioglu S, Lack N, Acilan C, Bagci-Onder T. Ddis-04. Mitoxantrone Potentiates Trail-Induced Apoptosis In Glioblastoma Multiforme Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.195  0.445
2016 Senbabaoglu F, Cingoz A, Kaya E, Kazancioglu S, Lack N, Acilan C, Bagci-Onder T. Mitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiforme European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32835-0  0.34
2015 Senbabaoglu F, Cingöz A, Kaya E, Kazancioglu S, Lack NA, Acilan C, Bagci-Onder T. Abstract B73: Screen among 1200 FDA-approved drug library reveals mitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiforme Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B73  0.564
2015 Kurt IC, Kahya Z, Kazancioglu S, Cingoz A, Lack N, Gumus ZH, Onder T, Onder TB. Epig-01The Function Of Chromatin-Modifying Enzymes In Gbm Cell Apoptosis. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov214.01  0.51
2015 Cingoz A, Gümüş ZH, Bagci-Onder T. Cbio-08Igfbp2 Is A Novel Molecular Determinant In Trail-Resistant Subpopulations Of Gbm Cell Lines Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov209.08  0.546
Show low-probability matches.